Philip Morris International (PM) boosted by strong Q1 earnings, product approvals
Philip Morris International shares are trading higher today, driven by robust first-quarter 2026 earnings and regulatory approval for its smoke-free products. The stock is currently at $168.96, up 3.1% from yesterday's close of $163.95 on 2026-04-22.
The company recently announced Q1 2026 results, reporting net revenues of $10.1 billion, an increase of 9.1%. Adjusted diluted earnings per share reached $1.96, up 16.0%. Smoke-free products accounted for 43% of net revenues, underscoring the company's strategic shift. Concurrently, the U.S. Food and Drug Administration reauthorised IQOS as a Modified Risk Tobacco Product, renewing MRTP orders for both IQOS 2.4 and IQOS 3 systems. This decision supports continued reduced-exposure communications for the product in the U.S. market.
Analyst sentiment also contributes to the upward movement, with a consensus price target of $192.56, representing a potential 13.7% upside. This follows a 7.0% gain on Wednesday, 2026-04-22, when the stock closed at $163.95.
What FDA Approval Means for Philip Morris International's Pivot
Philip Morris International manufactures and sells tobacco products, including cigarettes and a growing portfolio of smoke-free alternatives, to adult consumers across the globe. The company generates its revenue from the sale of these products, with a significant push towards reducing the health impact of smoking through innovative alternatives.
Today's upward movement in Philip Morris International's share price largely stems from the U.S. Food and Drug Administration's reauthorisation of IQOS as a Modified Risk Tobacco Product. This regulatory designation is crucial because it permits the company to communicate the product's reduced exposure benefits to consumers in the United States, effectively legitimising its strategic shift away from traditional cigarettes. This regulatory clarity, alongside robust first-quarter 2026 earnings that saw net revenues climb 9.1% to $10.1 billion, provides a strong tailwind for the business.
This combination of regulatory success and strong financial performance has seen the stock rise by exactly 3.1%, currently trading at $168.96.
Consider it like a company developing a new, more efficient engine for cars. Without official certification that the engine meets safety and emissions standards, its potential is limited, regardless of how good the internal test results are. The FDA's reauthorisation is that critical certification, allowing Philip Morris International to openly market its smoke-free product with its intended benefits, significantly de-risking its long-term growth strategy.
Philip Morris International
Philip Morris International Inc. (PM) operates within the Consumer Defensive sector, specialising in tobacco products. The company is actively transitioning towards a smoke-free future, diversifying its portfolio beyond traditional tobacco and nicotine offerings. Its product range encompasses both conventional cigarettes and a growing selection of smoke-free alternatives, including heat-not-burn, vapour, and oral nicotine products. These smoke-free innovations are marketed under various brands such as HEETS, Marlboro HeatSticks, and TEREA, alongside KT&G-licensed brands like Fiit and Miix. Traditional cigarette brands include Marlboro, Parliament, and Chesterfield, with regional brands such as Dji Sam Soe in Indonesia and Fortune in the Philippines. Philip Morris International distributes its smoke-free products across 71 markets, maintaining its headquarters in New York, New York, since its incorporation in 1987.